Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

Leuk Res. 2018 Nov;74:86-88. doi: 10.1016/j.leukres.2018.10.001. Epub 2018 Oct 5.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Male
  • Middle Aged
  • Organ Size / drug effects
  • Primary Myelofibrosis* / drug therapy
  • Primary Myelofibrosis* / metabolism
  • Primary Myelofibrosis* / pathology
  • Rituximab / administration & dosage*
  • Spleen* / metabolism
  • Spleen* / pathology
  • Time Factors

Substances

  • Rituximab